Analysts Set Qiagen N.V. (NYSE:QGEN) Price Target at $49.69

Qiagen N.V. (NYSE:QGEN) has earned an average rating of “Hold” from the ten research firms that are covering the stock, Marketbeat.com reports. Seven analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $49.6944.

A number of equities analysts recently weighed in on the company. Wall Street Zen upgraded Qiagen from a “hold” rating to a “buy” rating in a research report on Saturday, November 1st. UBS Group upped their price objective on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Barclays set a $53.00 target price on shares of Qiagen and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a report on Monday. Finally, Cowen restated a “hold” rating on shares of Qiagen in a research report on Thursday, August 7th.

Qiagen Trading Down 0.8%

Qiagen stock opened at $46.94 on Friday. The firm has a market cap of $10.43 billion, a price-to-earnings ratio of 27.73, a price-to-earnings-growth ratio of 2.48 and a beta of 0.64. Qiagen has a 1 year low of $37.63 and a 1 year high of $51.88. The firm’s 50 day moving average price is $46.35 and its two-hundred day moving average price is $46.94. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.03. The company had revenue of $532.58 million during the quarter, compared to the consensus estimate of $525.68 million. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.57 EPS. On average, research analysts predict that Qiagen will post 2.26 EPS for the current fiscal year.

Institutional Trading of Qiagen

Hedge funds and other institutional investors have recently modified their holdings of the business. SVB Wealth LLC acquired a new position in Qiagen during the first quarter valued at $31,000. Danske Bank A S purchased a new position in Qiagen during the 3rd quarter valued at about $36,000. Smartleaf Asset Management LLC increased its holdings in shares of Qiagen by 1,383.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after purchasing an additional 830 shares during the period. MAI Capital Management lifted its position in shares of Qiagen by 998.9% in the second quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after purchasing an additional 889 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of Qiagen by 400.5% in the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after purchasing an additional 849 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.